BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zurayk M, Keung Y, Yu D, Hu EH. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. J Oncol Pharm Pract 2019;25:234-8. [DOI: 10.1177/1078155217732141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Saif MW. Uridine triacetate - an antidote in the treatment of 5-fluorouracil or capecitabine poisoning. Expert Opinion on Orphan Drugs 2019;7:95-103. [DOI: 10.1080/21678707.2019.1591273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lampropoulou DI, Laschos K, Amylidi AL, Angelaki A, Soupos N, Boumpoucheropoulos S, Papadopoulou E, Nanou E, Zidianakis V, Nasioulas G, Fildissis G, Aravantinos G. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? J Oncol Pharm Pract. 2020;26:747-753. [PMID: 31382864 DOI: 10.1177/1078155219865597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Baldeo C, Vishnu P, Mody K, Kasi PM. Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications. SAGE Open Med Case Rep 2018;6:2050313X18786405. [PMID: 30013790 DOI: 10.1177/2050313X18786405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Leung M, Rogers JE, Shureiqi I. Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. Clin Colorectal Cancer 2021;20:273-8. [PMID: 33965356 DOI: 10.1016/j.clcc.2021.03.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]